ArticleNanotheranostics2020
Targeted Molecular Iron Oxide Contrast Agents for Imaging Atherosclerotic Plaque.
Article in Nanotheranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Molecular imaging research in atherosclerosis: A 23-year scientometric and visual analysis.Frontiers in bioengineering and biotechnology · 2023Pooled it
- A minimally invasive animal model of atherosclerosis and neointimal hyperplasia for translational research.European radiology experimental · 2025Article
- Superparamagnetic Nanoparticles with Phosphorescent Complexes as Hybrid Contrast Agents: Integration of MRI and PLIM.Small science · 2024Article
- Molecular imaging nanoprobes and their applications in atherosclerosis diagnosis.Theranostics · 2024Review
- Novel imaging modalities for the identification of vulnerable plaques.Frontiers in cardiovascular medicine · 2024Review
- Nanomedicines for cardiovascular disease.Nature cardiovascular research · 2023Review
- Challenges and opportunities in the development of metal-based anticancer theranostic agents.Bioscience reports · 2022Review
- Therapeutic Strategies and Chemoprevention of Atherosclerosis: What Do We Know and Where Do We Go?Pharmaceutics · 2022Review
- Molecular Imaging of Matrix Metalloproteinase-2 in Atherosclerosis Using a Smart Multifunctional PET/MRI Nanoparticle.International journal of nanomedicine · 2022Article
- Nanotechnological approach to delivering nutraceuticals as promising drug candidates for the treatment of atherosclerosis.Drug delivery · 2021Review
- Nanomaterials: Synthesis and Applications in Theranostics.Nanomaterials (Basel, Switzerland) · 2021Review
- Enzyme-activated probes in optical imaging: a focus on atherosclerosis.Dalton transactions (Cambridge, England : 2003) · 2021Review
- Iron Oxide Nanoparticles in Regenerative Medicine and Tissue Engineering.Nanomaterials (Basel, Switzerland) · 2021Review
- DNA Nanostructures and DNA-Functionalized Nanoparticles for Cancer Theranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.